[A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 05.04.2018

Project no.:

Commission awarded on 16.10.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy

Result of dossier assessment:

Advantage in overall survival and disadvantages regarding side effects; overall indication of minor added benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2018-04-05 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form